Latest Cormorant Asset Management, LP Stock Portfolio
$1.73Billion– No. of Holdings #47
Cormorant Asset Management, LP Performance:
2024 Q2: -9.27%YTD: -3.71%2023: 29.65%
Performance for 2024 Q2 is -9.27%, and YTD is -3.71%, and 2023 is 29.65%.
About Cormorant Asset Management, LP and 13F Hedge Fund Stock Holdings
Cormorant Asset Management, LP is a hedge fund based in BOSTON, MA. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $3.1 Billions. In it's latest 13F Holdings report, Cormorant Asset Management, LP reported an equity portfolio of $1.7 Billions as of 30 Jun, 2024.
The top stock holdings of Cormorant Asset Management, LP are MLTX, CRBP, ACLX. The fund has invested 21.6% of it's portfolio in MOONLAKE IMMUNOTHERAPEUTICS and 5.3% of portfolio in CORBUS PHARMACEUTICALS HLDGS.
The fund managers got completely rid off ALPINE IMMUNE SCIENCES INC (ALPN), AUTOLUS THERAPEUTICS PLC (AUTL) and ALX ONCOLOGY HLDGS INC (ALXO) stocks. They significantly reduced their stock positions in NEUROGENE INC, TARSUS PHARMACEUTICALS INC (TARS) and COMPASS THERAPEUTICS INC (CMPX). Cormorant Asset Management, LP opened new stock positions in RAPPORT THERAPEUTICS INC, AXSOME THERAPEUTICS INC (AXSM) and UROGEN PHARMA LTD (URGN). The fund showed a lot of confidence in some stocks as they added substantially to CENTESSA PHARMACEUTICALS PLC (CNTA), VAXCYTE INC (PCVX) and NEWAMSTERDAM PHARMA COMPANY (NAMS).
The top stock holdings of Cormorant Asset Management, LP are MLTX, CRBP, ACLX. The fund has invested 21.6% of it's portfolio in MOONLAKE IMMUNOTHERAPEUTICS and 5.3% of portfolio in CORBUS PHARMACEUTICALS HLDGS.
The fund managers got completely rid off ALPINE IMMUNE SCIENCES INC (ALPN), AUTOLUS THERAPEUTICS PLC (AUTL) and ALX ONCOLOGY HLDGS INC (ALXO) stocks. They significantly reduced their stock positions in NEUROGENE INC, TARSUS PHARMACEUTICALS INC (TARS) and COMPASS THERAPEUTICS INC (CMPX). Cormorant Asset Management, LP opened new stock positions in RAPPORT THERAPEUTICS INC, AXSOME THERAPEUTICS INC (AXSM) and UROGEN PHARMA LTD (URGN). The fund showed a lot of confidence in some stocks as they added substantially to CENTESSA PHARMACEUTICALS PLC (CNTA), VAXCYTE INC (PCVX) and NEWAMSTERDAM PHARMA COMPANY (NAMS).
Cormorant Asset Management, LP Equity Portfolio Value
Last Reported on: 14 Aug, 2024
Cormorant Asset Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Cormorant Asset Management, LP made a return of -9.27% in the last quarter. In trailing 12 months, it's portfolio return was 16.78%.
New Buys
| Ticker | $ Bought |
|---|---|
| rapport therapeutics inc | 68,391,000 |
| axsome therapeutics inc | 32,200,000 |
| alumis inc | 28,560,400 |
| urogen pharma ltd | 27,687,000 |
| sarepta therapeutics inc | 19,750,000 |
| cullinan therapeutics inc | 19,620,000 |
| y-mabs therapeutics inc | 17,516,000 |
| avidity biosciences inc | 17,361,200 |
New stocks bought by Cormorant Asset Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| centessa pharmaceuticals plc | 186 |
| vaxcyte inc | 60.58 |
| newamsterdam pharma company | 53.33 |
| janux therapeutics inc | 40.00 |
| biohaven ltd | 29.99 |
| cg oncology inc | 21.88 |
| eyepoint pharmaceuticals inc | 20.77 |
| arcutis biotherapeutics inc | 18.82 |
Additions to existing portfolio by Cormorant Asset Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| neurogene inc | -80.07 |
| tarsus pharmaceuticals inc | -76.63 |
| compass therapeutics inc | -63.48 |
| korro bio inc | -49.77 |
| praxis precision medicines i | -47.71 |
| ideaya biosciences inc | -45.56 |
| bridgebio pharma inc | -41.98 |
| longboard pharmaceuticals in | -16.78 |
Cormorant Asset Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| autolus therapeutics plc | -42,214,300 |
| immuneering corp | -9,523,340 |
| marinus pharmaceuticals inc | -29,380,000 |
| alx oncology hldgs inc | -35,034,200 |
| ventyx biosciences inc | -14,905,000 |
| alpine immune sciences inc | -107,028,000 |
| nkarta inc | -14,593,500 |
| astria therapeutics inc | -18,297,500 |
Cormorant Asset Management, LP got rid off the above stocks
Sector Distribution
Cormorant Asset Management, LP has about 81.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 81.9 |
| Others | 18.1 |
Market Cap. Distribution
Cormorant Asset Management, LP has about 3.8% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 48 |
| SMALL-CAP | 25.9 |
| UNALLOCATED | 20.7 |
| LARGE-CAP | 3.8 |
| MICRO-CAP | 1.4 |
Stocks belong to which Index?
About 45.6% of the stocks held by Cormorant Asset Management, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 54.4 |
| RUSSELL 2000 | 45.6 |
Cormorant Asset Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Cormorant Asset Management, LP
Cormorant Asset Management, LP has 47 stocks in it's portfolio. About 58.5% of the portfolio is in top 10 stocks. EYPT proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Cormorant Asset Management, LP last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 4.86 | 1,525,000 | 84,164,800 | reduced | -14.33 | ||
| AGLE | spyre therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALPN | alpine immune sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALXO | alx oncology hldgs inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APLS | apellis pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARQT | arcutis biotherapeutics inc | 1.36 | 2,525,000 | 23,482,500 | added | 18.82 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AUTL | autolus therapeutics plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTE | aerovate therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AXSM | axsome therapeutics inc | 1.86 | 400,000 | 32,200,000 | new | |||
| BBIO | bridgebio pharma inc | 2.72 | 1,858,350 | 47,072,000 | reduced | -41.98 | ||
| BCAB | bioatla inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BMEA | biomea fusion inc | 0.93 | 3,570,870 | 16,068,900 | unchanged | 0.00 | ||
| CABA | cabaletta bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CGEM | cullinan therapeutics inc | 1.13 | 1,125,000 | 19,620,000 | new | |||
| CMPX | compass therapeutics inc | 0.12 | 2,030,820 | 2,030,820 | reduced | -63.48 | ||
| CNTA | centessa pharmaceuticals plc | 0.84 | 1,611,600 | 14,552,700 | added | 186 | ||
| CRBP | corbus pharmaceuticals hldgs | 5.29 | 2,025,000 | 91,631,200 | unchanged | 0.00 | ||
| CRNX | crinetics pharmaceuticals in | 3.49 | 1,350,000 | 60,466,500 | added | 17.39 | ||
| EWTX | edgewise therapeutics inc | 3.13 | 3,006,530 | 54,147,700 | unchanged | 0.00 | ||